Summary Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
5-Fluorouracil (5-FU)-associated cardiotoxicity was recognized 18 years after its first clinical use, after symptoms of chest pain typical of angina pectoris, in patients treated with 5-FU (Dent and McColl, 1965) . Estimates of its incidence have been given with a range of 1.6% in larger series (Labianca et al, 1982) and up to 10% in smaller cohorts (Collins and Weiden, 1987) . 5-FU should be discontinued in the case of cardiotoxicity to avoid the development of serious or fatal cardiac damage (Anand, 1994) . However, the arsenal of effective antineoplastic compounds for the treatment of colorectal cancer is limited, and the identification of a drug that may be safely given to patients with cardiac toxicity after 5-FU administration is important. Here, we report the successful administration of raltitrexed (Zeneca, Macclesfield, Cheshire, UK), a new specific thymidylate synthase inhibitor, in two patients with 5-FU-induced cardiotoxicity.
PATIENTS AND METHODS Case 1
A 58-year-old female without any history of cardiovascular disease presented at our institution with lung and liver metastases of a sigmoid adenocarcinoma. She had received three cycles of weekly folinic acid 500 mg m-2 as a 2-h infusion and 5-FU 500 mg m-2 as an i.v. bolus in the middle of the folinic acid infusion repeated for 6 weeks followed by a 2-week rest period. This therapy was tolerated well without any cardiac toxicity. When the tumour progressed, treatment with high-dose 5-FU 2600 mg m-2 given as a weekly 24-h infusion plus folinic acid 500 mg m-2 as a 2-h infusion before 5-FU was initiated. Approximately 22 h after the start of the 5-FU infusion the patient complained of dyspnoea and retrosternal pain and the 5-FU infusion was stopped. The blood pressure was 80/60 mmHg and the heart rate was regular with 100 beats per min. The ECG obtained after onset of symptoms revealed non-specific ST segment elevation in the anterior and posterior leads with a normalization after 24 h (Figures 1 and  2 ). Serial measurements of serum cardiac enzymes were normal. One week later, the patient was given the same 5-FU/folinic acid regimen and also received isosorbide dinitrate, molsidomine and acetylsalicylic acid. Approximately 10 h after the start of the 5-FU infusion, the patient complained of dyspnoea and retrosternal chest pain. The Four weeks later, an unremarkable stress ECG confirmed the patient's well-being. An echocardiogram showed a normal global ejection fraction. The patient then received four cycles of raltitrexed 3 mg m-2 as a short i.v. infusion every 3 weeks. This treatment was well tolerated without any incidence of cardiac toxicity. When the tumour progressed after the fourth cycle of raltitrexed, he received bolus 5-FU 425 mg m-2 plus FA 20 mg m-2 given on 5 consecutive days every 4 weeks. Eight hours after the second administration on day 2, the patient complained of retrostemal chest pain that again only temporarily responded to nitroglycerine. The ECG recorded shortly after the pain episode demonstrated T-wave depression in the anterior leads, which resolved three days after the event (Figures 3 and 4) . Coronary angiography revealed no restenosis of the formerly treated LAD bypass graft. The symptoms of retrostemal chest pain were therefore most likely due to 5-FU cardiotoxicity. The patient remained stable and without episodes of.angina pectoris thereafter.
DISCUSSION
We present two cases of repeated 5-FU induced cardiotoxicity with no cardiac side-effects after repeated exposure to raltitrexed. Our first patient had normal coronary arteries as demonstrated by coronary catheterization. She experienced retrostemal chest pain accompanied by ECG changes on repeated administration of high dose infusional 5-FU but had previously tolerated a weekly bolus regimen. This is a notable observation, which to our knowledge has not been described before and supports the proposed dose-and/or schedule-dependency of 5-FU induced cardiotoxicity (Collins and Weiden, 1987; Gamelin et al, 1991; Weidmann et al, 1994) . Therefore, it remains possible that our patient might have tolerated bolus 5-FU without cardiotoxicity. After experiencing 5-FU cardiotoxicity, she could safely receive raltitrexed without cardiac symptoms or ECG changes on repeated recordings during raltitrexed treatment.
Our second patient was asymptomatic without angina pectoris for several years after a coronary artery bypass operation and required minimal anti-anginal medication. During the infusion of high dose 5-FU he experienced retrosternal chest pain accompanied by ECG changes in the anterior and posterior leads. Therefore, the detection of a significant stenosis in the LAD bypass supplying the anterior wall does not contradict the postulated role of 5-FU as a causative agent. Additionally, the retrostemal chest pain accompanied by ECG changes occurred again when this stenosis was open. The time correlation between 5-FU exposure and cardiac symptoms at rest, and the reversibility of ECG changes strongly argue in favour of 5-FU as the causative agent of this patient's cardiac symptoms, even if it might be a combination of both. It is therefore reasonable to assume that this patient had 5-FU-induced cardiotoxicity as well as ischaemic heart disease. Patients with a history of coronary heart disease are more likely to experience 5-FU cardiotoxicity (Labianca et al, 1982) . It may be for this reason that our patient had toxicity when receiving bolus (low dose) and infusional (high dose) 5-FU. This patient also received several cycles of raltitrexed without any further episodes of chest pain or ECG changes.
Several causative mechanisms for 5-FU cardiotoxicity have been postulated, including an autoimmune response to damaged cells (Stevenson et al, 1977) , increased oxygen demand in patients receiving 5-FU (Rezkalla et al, 1989) , coronary spasm (Burger and Mannino, 1987) due to protein kinase C-mediated vasoconstriction (Mosseri et al, 1993 ) and the 5-FU contaminant fluoroacetate (FAC) (Lemaire et al, 1992) .
It has been suggested that the cardiotoxic effect of 5-FU itself may be responsible for 5-FU cardiotoxicity (Villani et al, 1979) . Inhibition of DNA synthesis by 5-FU incorporated into myocardial cells was suggested to be the first step of cardiotoxicity (Liss and Chadwick, 1974) , and myocardial depression has been explained by inhibition of mitochondrial DNA synthesis due to 5-FU (Akhtar et al, 1993) . Like 5-FU, raltitrexed exerts similar effects on DNA synthesis. This DNA-directed antimetabolite mechanism is therefore a very unlikely cause of 5-FU cardiotoxicity. As the recurrence rate of cardiotoxicity after exposure to 5-FU is thought to be 90% (Robben et al, 1993) , cardiotoxic side-effects after a total of seven exposures to raltitrexed would have been expected, assuming that the direct cytotoxic effect on DNA synthesis is responsible for cardiotoxicity.
Usually, 5-FU based treatment has to be discontinued if the patient experiences cardiotoxicity (Anand, 1994) . The choice of effective alternative drugs is limited in patients with colorectal cancer. In metastatic disease, 5-FU-based therapy improves the quality of life, delays the occurrence of tumour-related symptoms (Anonymous, 1992) and may prolong survival compared with patients not receiving chemotherapy (Scheithauer et al, 1993) . Therefore it is important to offer those patients an effective alternative treatment. Based on our experience, raltitrexed may be a candidate. The precise role of this drug relative to 5-FU plus folinic acid is currently under investigation. Three randomized trials (Cunningham et al, 1995; Harper, 1997; Pazdur and Vincent, 1997) demonstrated equivalence in the response rates, two of these studies showed a slightly inferior time to progression (4 weeks) and one trial a shorter median survival (9.7 vs 12.7 months) for patients receiving raltitrexed, while the other studies demonstrated no survival difference compared with 5-FU/leucovorin bolus schedules. Although these small differences were statistically significant, they may not be clinically relevant when clinicians have to decide for an individual patient.
